Skip to content

A clinical study to assess the safety and effectiveness of test products in healthy adult human subjects having hair fall complaints.

A prospective, interventional, open-label, non-randomized, two-arm, parallel, clinical safety, efficacy and in-use tolerability study of the two test products in healthy adult human subjects having hair fall complaints (alopecia i.e. more than 100 hairs fall per day). - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070860
Enrollment
60
Registered
2024-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Soulflower Rosemary Essential Oil : Test Product : Soulflower Rosemary Essential Oil Marketed By: Soulflower – PT INVENT INDIA PVT LTD Mode of Usage: Mix 5 drops of the oil with 1 table

Sponsors

Soulflower – PT INVENT INDIA PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: 18 to 55 years (both inclusive) at the time of consent. 2) Sex: Healthy non-pregnant/non-lactating females. 3) Females of childbearing potential must have a self-reported negative pregnancy test. 4) Subject are generally in good health. 5) Subject with more than 100 hair fall per day. 6) Subject with self-assessed complaint of thinning of hair. 7) Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 8) If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 9) If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study. 10) Subjects are willing to give written informed consent and are willing to follow the study procedure. 11) Subjects who commit not to use medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth hair products or hair colour or dye, other than the test products for the entire duration of the study. 12) Willing to use test product throughout the study period

Exclusion criteria

Exclusion criteria: 1) History of any dermatological condition of the scalp other than hair loss. 2) History of prior use of hair growth treatment within 3 months. 3) History of any prior hair growth procedures (e.g., hair transplant or laser). 4) Subjects who have applied topical treatment for hair loss for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study. 5) Subject who perform any salon treatment on hair including haircut during the study period. 6) History of alcohol or drug addiction. 7) Subjects using other marketed hair fall control and/or hair growth products during the study period. 8) Subjects who have plans of shaving scalp hair during the study. 9) Subjects who are on chronic oral steroids 03 months before initial application and during the study period. 10) History or present condition of irritated or visibly inflamed scalp or severe scalp disease. 11) Subjects having a history or present condition of an allergic response to any cosmetic products. 12) Any other condition which could warrant exclusion from the study, as per the dermatologist’s/investigator’s discretion. 13) Pregnant or breastfeeding or planning to become pregnant during the study period. 14) History of chronic illness which may influence the cutaneous state. 15) Subjects participating in other similar cosmetics, devices or therapeutic trials or hair/scalp care products within the last four weeks.

Design outcomes

Primary

MeasureTime frame
To evaluate the effectiveness of the test products in terms of 1.change in hair growth rate from baseline before and after usage of the test products. 2. change in hair density, hair thickness from baseline before and after usage of the test products. 3.change in hair length from baseline before and after usage of the test products. 4. change in hair fall reduction from baseline before and after usage of the test products.Timepoint: Day 04 before Day 01, Day 01, and after test product usage on Day 45, Day 87 and Day 90

Secondary

MeasureTime frame
To evaluate the effectiveness of the test products in terms of 1.change in hair root strength and scalp condition and A:T ratio. 2.change in general appearance of the hair and scalp 3. subject perception questionnaire.Timepoint: Day 04 before Day 01, Day 01, and after test product usage on Day 45, Day 87 and Day 90

Countries

India

Contacts

Public ContactMaheshvari Patel

NovoBliss Research Private Limited

dr.nayan@novobliss.in7948983895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026